LONDON, November 26, 2020 / PRNewswire / – Haoma Medica today announced the completion of a first trial in humans for NaQuinate, a naphthoquinone carboxylic acid, which is under development as a new orally administered therapeutic for osteoporosis.
The first human trial started in healthy adults last year studied single and multiple doses of NaQuinate. The primary goal was to assess safety, tolerability and pharmacokinetics.
“We are pleased that the first human study has completed the final dosing. There were no significant safety or tolerability concerns up to the highest doses tested, underscoring our expectation that NaQuinate is safe and well-tolerated, ” said Dr. Cenk Oguz, Chief Medical Officer of Haoma Medica.
Our preclinical research has uncovered an exciting feature of NaQuinate, where it appears to be able to work in harmony with the body’s natural response to weight-bearing exercise to synergistically improve bone formation when and where needed – that would “drug,” said Dr. Steve Deacon, CEO of Haoma Medica. Together with the safety data from this first human study, this supports the potential that the NaQuinate treatment can provide a safe, novel and smart therapeutic approach to bone disorders such as osteoporosis and better maintain healthy skeletal aging.
Previous studies have shown that NaQuinate protects against bone quality and quantity reduction that occurs in response to ovariectomy in rodent models. In a mechanical mouse loading model, a surrogate for weight-bearing exercise, NaQuinate synergistically enhanced the body’s normal response to loading by forming bone, targeting relevant cortical bone areas. This synergistic interaction between NaQuinate and mechanical loading suggests the functional use of the mechanostat of bone, a term that describes how mechanical loading affects bone structure, in the regulation of bone mass and architecture. NaQuinate is currently being evaluated using a curative model of osteoporosis versus a bisphosphonate and a loading model versus an anabolic; results are expected early next year.
Osteoporosis is a silent disease that often shows no signs or symptoms until a fracture occurs. So it remains an underdiagnosed and undertreated disease.
Osteoporosis results in bone loss and changes in bone quality and strength that occur during the normal aging process, leading to fragile bones. Fragile bones lead to fractures, which spiral into a downward spiral of disability, loss of independence and increased mortality with significant social and economic burdens. Fragility fractures are a major obstacle to healthy aging. Worldwide there is a fragility fracture every 3 seconds.
About 200 million people worldwide suffer from the disease, according to the International Osteoporosis Foundation. A combined lifetime risk of fracture is 40% and corresponds to the risk of cardiovascular disease. In women over the age of 45, osteoporosis results in more time in hospitals than many other diseases such as breast cancer, heart attacks and diabetes.
About Haoma Medica
Haoma Medica is a clinical-stage biotechnology company focused on the development of therapies to maintain bone and blood vessel health.
For more information, please visit www.haomamedica.com
Investor Relations Contact:
Name: Carmen Greco
email: [email protected]
Logo – https://mma.prnewswire.com/media/1251548/Haoma_Medica_Logo.jpg
View original content: http: //www.prnewswire.com/news-releases/haoma-medica-completes-first-in-human-trial-for-naquinate-a-novel-treatment-in-development-for-osteoporosis- 301181026.html
SOURCE Haoma Medica